Advancing Autologous Stem Cell Therapy for Parkinson’s: Key Findings from a Preclinical Study
A preclinical study evaluating human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic cells (mDACs) for Parkinson’s disease highlights key safety and efficacy factors, opening the way for an upcoming clinical trial.
